Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the EU
Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 30, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Diabetes Patient care blood pressure body weight empagliflozin/metformin HCl Latest News safety profile type 2 diabetes Source Type: news
New WHO report shows that transparency and cooperation help to reduce high prices for new medicines
The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost effectiveness of new drugs; this hampers the value-assessment and decision-making processes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Affordability Latest News national health systems new medicines WHO regional office Source Type: news
Allpresan® diabetic foam creams launch in the UK
Neubourg Pharma UK announces the launch of Allpresan Diabetic Foot Foam Creams into the UK, clinically formulated to treat and prevent dry cracked skin and calluses on diabetic feet, the first clinically and medically approved to be used between toes safely. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 19, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Dermatology Diabetes Patient care diabetic feet dry skin Latest News type 1 diabetes Source Type: news
Ablynx initiates the first of two Phase IIb RA studies with its anti-IL-6R nanobody, partnered with Abbvie
Ablynx announced that it has administered the first dose in the Phase IIb study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in combination with methotrexate (MTX) in adult patients with active RA, despite MTX therapy. The study aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 19, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Drug development Rheumatology Patient care anti-IL-6R DMARD Latest News methotrexate nanobody rheumatoid arthritis Source Type: news
First European study of Tresiba® shows improved blood glucose control and reduced hypoglycaemia risk
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 11, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News UK Conference and Symposia Diabetes Endochrine Disorders Conference reports Patient care blood glucose control clinical practice hypoglycaemia insulin degludec Source Type: news
Amgen announces the EMA acceptance of kyprolis® marketing authorisation application
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) of Kyprolis® (carfilzomib) for injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 10, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Other conferences & symposia Oncology Patient care carfilzomib EMA Latest News multiple myeloma Source Type: news
AOP Orphan Pharmaceuticals announces progress of Phase III Trial PROUD-PV
Ropeginterferon alfa 2b is a novel, long-acting, mono-pegylated Interferon, administered only once every 14 days, after achieving therapy response even only monthly.
Based on previous Phase I/II trials, Ropeginterferon alfa 2b is expected to be safe and effective in the majority of PV patients.
Haematological and molecular responses occured in most patients; moreover, several patients achieved undetectable mutated JAK2 levels and a complete normalisation of their chromosomal make-up. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 10, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care JAK2 Latest News myeloproliferative neoplasms Polycythemia Vera PROUD-PV Ropeginterferon alfa 2b Source Type: news
83% of British people recognise chronic pain as a serious medical condition, only 15% get treatment
Almost 10 million people in the UK suffer from chronic pain, which has a major impact on quality of life and day to day activities, such as work; (1) however many of those people do not have their pain under control or know how to go about seeking the right treatment. A survey, which was conducted by St. Jude Medical in collaboration with Pain UK, recently interviewed 1614 people (1090 general respondents and 524 chronic pain sufferers) and found that although chronic pain is quite prevalent, there is a general lack of awareness about what chronic pain is and how it should be treated. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 5, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick chronic pain Latest News quality of life surgery trauma Source Type: news
Mundipharma launches Remsima®, a new-generation value-based monoclonal antibody
• The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications
• Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy
• Biosimilar monoclonal antibodies are expected to save European healthcare systems between €1.8 and €20.4 billion between 2007 and 2020 (1) (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 3, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Practical therapeutics Cost effectiveness Industry News mAbs Legislation & regulation Gastroenterology Patient care efficacy inflammatory autoimmune diseases Latest News reference product remicad Source Type: news
Apeiron announces start of Phase I trial
Apeiron’s project APN401, based on the collection, stimulation and subsequent re-administration of a patient’s immune cells, is being investigated in a clinical Phase I trial performed at a renowned, academic medical centre in the United States. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 26, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Drug development Oncology Patient care Research Apeiron APN311 Latest News SIOPEN study group Source Type: news
EMA-approved Remsima™ could reduce cost of treating Crohn’s disease
Celltrion Healthcare has announced data demonstrating the healthcare savings achievable by using Remsima™ (CT-P13), a biosimilar monoclonal antibody infliximab, to treat patients with Crohn’s disease (CD) in France, Italy and the UK. (1) (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 20, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Practical therapeutics Industry News mAbs Gastroenterology Patient care biosimilar monoclonal antibody crohn's disease Latest News Remsima Source Type: news
At the dawn of biosimilar insulins
The European Medicines Agency introduced the term 'biosimilars' into their legislation in 2004 to allow for marketing authorisation of biological therapeutics and in 2014 Abasria® was approved for the treatment of type 1 and type 2 diabetes (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2015 Category: Drugs & Pharmacology Authors: ebercott Tags: Diabetes Featured Articles Source Type: news
Anti-TNF therapy in inflammatory bowel disease
Inflammatory bowel disease has been revolutionised by anti-tumour necrosis factor therapy and therapeutic drug monitoring can optimise and guide future treatment decisions (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2015 Category: Drugs & Pharmacology Authors: ebercott Tags: Gastroenterology Featured Articles Source Type: news
Remodelling delivery of mAbs in rheumatoid arthritis
Tocilizumab, a monoclonal antibody targeted at the interleukin-6 receptor, is now available as a subcutaneous formulation for the management of moderate to severe rheumatoid arthritis (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2015 Category: Drugs & Pharmacology Authors: ebercott Tags: Rheumatology Featured Articles Source Type: news
New treatment regimens in chronic hepatitis C
New drugs, such as simeprevir, sofosbuvir and daclatasvir, have the advantage of once-daily dosing, fewer adverse effects and efficacy against multiple hepatitis C virus genotypes (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2015 Category: Drugs & Pharmacology Authors: ebercott Tags: Hepatic disorders Featured Articles Source Type: news
